Scholarlink

<p>Difficulties with polypharmacy are a&#xa0;recognized problem in geriatric patients suffering from multimorbidity. Clinical science has developed several solutions to this problem. The most widely endorsed approach is the use of medication lists, which methodically categorize substances or substance classes. The risk of drug interactions or prescription cascades increases with the number of medications. In the case of severe frailty or life-limiting disease within a&#xa0;palliative context, modification of treatment objectives is imperative. Reevaluation of the existing pharmacotherapy is required. In order to correspond most individually to patients’ wishes and values, substantial knowledge of patients’ needs and contextual factors (physical and psychological symptom burden, availability of care, social situation) is essential. This is necessary for a&#xa0;good risk–benefit analysis under patients’ involvement.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aspekte einer palliativen Pharmakotherapie bei geriatrischen Patienten: Was macht noch Sinn bei höhergradiger Frailty?

  • 期刊论文

  • 发表日期：

    2026年1月16日

查看全文
  • Achim Rehlaender,
  • E. V. Pfeiffer

摘要

Difficulties with polypharmacy are a recognized problem in geriatric patients suffering from multimorbidity. Clinical science has developed several solutions to this problem. The most widely endorsed approach is the use of medication lists, which methodically categorize substances or substance classes. The risk of drug interactions or prescription cascades increases with the number of medications. In the case of severe frailty or life-limiting disease within a palliative context, modification of treatment objectives is imperative. Reevaluation of the existing pharmacotherapy is required. In order to correspond most individually to patients’ wishes and values, substantial knowledge of patients’ needs and contextual factors (physical and psychological symptom burden, availability of care, social situation) is essential. This is necessary for a good risk–benefit analysis under patients’ involvement.